Head-To-Head Analysis: Aerie Pharmaceuticals (AERI) & Arcturus Therapeutics (ARCT)
Aerie Pharmaceuticals (NASDAQ: AERI) and Arcturus Therapeutics (NASDAQ:ARCT) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.
This is a breakdown of recent ratings and target prices for Aerie Pharmaceuticals and Arcturus Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Volatility and Risk
Aerie Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500.
This table compares Aerie Pharmaceuticals and Arcturus Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Aerie Pharmaceuticals and Arcturus Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aerie Pharmaceuticals||N/A||N/A||-$99.05 million||($4.08)||-13.10|
|Arcturus Therapeutics||N/A||N/A||-$24.60 million||($3.99)||-1.40|
Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
99.0% of Aerie Pharmaceuticals shares are held by institutional investors. 9.4% of Aerie Pharmaceuticals shares are held by insiders. Comparatively, 0.0% of Arcturus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Arcturus Therapeutics beats Aerie Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan). The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. Its Rhopressa is a once-daily eye drop. Rhopressa inhibits Rho kinase (ROCK), and the norepinephrine transporter (NET), which are both biochemical targets for lowering IOP. Its Roclatan is a once-daily, fixed-dose combination of Rhopressa and latanoprost, which is a prescribed drug for the treatment of patients with open-angle glaucoma. The Company is engaged in conducting Phase III clinical trial for Roclatan.
About Arcturus Therapeutics
Arcturus Therapeutics Ltd, formerly Alcobra Ltd, is an Israel-based preclinical-stage biopharmaceutical company primarily focused on the discovery, development and commercialization of ribonucleic acid (RNA) medicines using lipid-mediated nanoparticle delivery system (LUNAR) and Unlocked Nucleomonomer Agent (UNA) Oligomer chemistry technology platforms. The Company, through Arcturus Therapeutics Inc, its wholly owned subsidiary based in the United States, is focused on developing RNA medicines for rare, infectious, fibrotic and respiratory diseases with unmet medical needs, including cystic fibrosis, nonalcoholic steatohepatitis (NASH) and rare liver diseases, as well as replicon RNA vaccines.
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.